Cargando…

P31 Impact of COVID-19 on HTA/PRMA of Medicinal Products in Europe: A Payer Perspective

Detalles Bibliográficos
Autores principales:	Mycka, J, Dellamano, R, Lobb, W, Dalal, N, Dellamano, L, Pereira, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769652/ http://dx.doi.org/10.1016/j.jval.2021.11.030

Ejemplares similares

HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
por: Hutcheson, R, et al.
Publicado: (2022)

[(177)Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective
por: Spada, Francesca, et al.
Publicado: (2021)

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
por: Wang, Ting, et al.
Publicado: (2022)

RADIATION EXPOSURE DURING SPINE SURGERY USING C-ARM FLUOROSCOPY
por: Cristante, Alexandre Fogaça, et al.
Publicado: (2019)

The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018)

Molecular determinants of improved cathepsin B inhibition by new cystatins obtained by DNA shuffling
por: Valadares, Napoleão F, et al.
Publicado: (2010)

Microalgae population dynamics in photobioreactors with secondary sewage effluent as culture medium
por: Marchello, Adriano E., et al.
Publicado: (2015)

HTA56 COVID-19 from the Perspective of Intellectual Property
por: Pereira da Veiga, CR, et al.
Publicado: (2022)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

Value Insider Season 1 Episode 1: The Importance of Payers and HTA: How Did We End Up Here? (Introduction to Value) [Podcast]
por: Drummond, Michael F, et al.
Publicado: (2022)

Payer Perspectives on Health Technology Assessment
por: Watkins, John B.
Publicado: (2012)

Impact of COVID-19 pandemic on HTA
Publicado: (2020)

HTA and National Immunisation Program: an overview of competent bodies and of the impact of HTA on the decision-making process
por: Ricciardi, W
Publicado: (2022)

Why we should have more collaboration on HTA in Europe: the example of sofosbuvir
por: Schelleman, Hedi, et al.
Publicado: (2015)

Systematic literature review on the implicit factors influencing the HTA deliberative process in Europe
por: Monleón, Clara, et al.
Publicado: (2022)

Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada
por: Tony, Michèle, et al.
Publicado: (2011)

Patient advocate perspectives on involvement in HTA: an international snapshot
por: Scott, Anna Mae, et al.
Publicado: (2017)

How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice
por: Tafuri, Giovanni, et al.
Publicado: (2016)

Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective
por: Kisser, Agnes, et al.
Publicado: (2021)

The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective
por: Pastor-Quirós, Luis J., et al.
Publicado: (2021)

Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA: Comment on "Ethics in HTA: Examining the ‘Need for Expansion’"
por: Culyer, Anthony J.
Publicado: (2019)

Assessing payer perspectives on health information exchange
por: Cross, Dori A, et al.
Publicado: (2016)

Pharmaceutical Technology Assessment: Perspectives from Payers
por: Leung, Musetta Y., et al.
Publicado: (2012)

Navigating HTA implementation: a review of Indonesia’s revised HTA guideline
por: Chavarina, Kinanti Khansa, et al.
Publicado: (2023)

GMS-HTA: Information out of the world of HTA - up-to-date, comprehensive and valid
por: Rüther, Alric
Publicado: (2005)

Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges
por: Daubner-Bendes, Rita, et al.
Publicado: (2021)

2.G. Workshop: The development of HTA collaboration in Europe: where we are and where we are going
Publicado: (2022)

Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs
por: Epstein, Robert S
Publicado: (2021)

Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years’ multi-stakeholder dialogue on improving access in Europe via MoCA
por: Cavaller-Bellaubi, Maria, et al.
Publicado: (2023)

HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations
por: Hoxhaj, Ilda, et al.
Publicado: (2022)

HTA challenges for personalized medicine: the case of liquid biopsy for lung cancer
por: Aguilera-Cobos, L, et al.
Publicado: (2023)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
por: Lach, Krzysztof, et al.
Publicado: (2017)

Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio
por: Molfenter, Todd, et al.
Publicado: (2015)

Health Care Leaders’ Perspectives on the Maryland All-Payer Model
por: Kilaru, Austin S., et al.
Publicado: (2022)

Discounts and rebates granted to public payers for medicines in European countries
por: Vogler, Sabine, et al.
Publicado: (2012)

The impact of HTA reports on health policy: a systematic review
por: Gerhardus, Ansgar, et al.
Publicado: (2005)

POSC254 The Impact of COVID-19 on European HTA Decisions
por: Watson, C, et al.
Publicado: (2022)

Hospitals and the Tax-Payer
Publicado: (1920)

HTA26 Health Technology Assessment (HTA) Methods for Monoclonal Antibodies for Treatment and Prevention of COVID-19
por: Warttig, S, et al.
Publicado: (2022)

Use of Surrogate end points in HTA
por: Mangiapane, Sandra, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_7np9dbpulgb4ho804erjocqlju